{
    "ticker": "BIIB",
    "name": "Biogen Inc.",
    "description": "Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases. Founded in 1978 by a group of scientists at Harvard University, Biogen has established itself as a leader in the biopharmaceutical industry, focusing on serious conditions such as multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer's disease. The company's pioneering MS treatments, including Avonex and Tecfidera, have transformed the lives of patients worldwide. Biogen is also at the forefront of research aimed at addressing Alzheimer's disease, with its FDA-approved treatment, Aduhelm, being a significant milestone in the field. With a commitment to research and development, Biogen invests heavily in advancing scientific knowledge and innovation to improve patient outcomes. The company operates globally, with a strong presence in North America and Europe, and collaborates with various research institutions to enhance its therapeutic approaches. Biogen\u2019s mission is to provide hope and solutions for patients affected by debilitating neurological conditions, driving progress in the biotechnology landscape with a focus on science, integrity, and collaboration.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "1978",
    "website": "https://www.biogen.com",
    "ceo": "Christopher A. Viehbacher",
    "social_media": {
        "twitter": "https://twitter.com/Biogen",
        "linkedin": "https://www.linkedin.com/company/biogen/"
    },
    "investor_relations": "https://investors.biogen.com",
    "key_executives": [
        {
            "name": "Christopher A. Viehbacher",
            "position": "CEO"
        },
        {
            "name": "Michael D. Ehlers",
            "position": "Executive Vice President, Research and Development"
        }
    ],
    "product_categories": [
        {
            "category": "Neurology",
            "products": [
                "Avonex",
                "Tecfidera",
                "Aduhelm"
            ]
        },
        {
            "category": "Rare Diseases",
            "products": [
                "Spinraza"
            ]
        }
    ],
    "seo": {
        "meta_title": "Biogen Inc. | Innovating Neurological Therapies",
        "meta_description": "Explore Biogen Inc., a leader in biotechnology focused on neurological and neurodegenerative diseases. Discover our innovative therapies and commitment to research.",
        "keywords": [
            "Biogen",
            "Biotechnology",
            "Neurology",
            "Multiple Sclerosis",
            "Alzheimer's Disease",
            "Aduhelm",
            "Spinraza"
        ]
    },
    "faq": [
        {
            "question": "What does Biogen specialize in?",
            "answer": "Biogen specializes in developing therapies for neurological and neurodegenerative diseases."
        },
        {
            "question": "Who is the CEO of Biogen?",
            "answer": "The CEO of Biogen is Christopher A. Viehbacher."
        },
        {
            "question": "Where is Biogen headquartered?",
            "answer": "Biogen is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Biogen's main products?",
            "answer": "Biogen's main products include Avonex, Tecfidera, Aduhelm, and Spinraza."
        },
        {
            "question": "When was Biogen founded?",
            "answer": "Biogen was founded in 1978."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX",
        "CELG"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "ABBV"
    ]
}